Can-Fite BioPharma, the parent company of OphthaliX, received a patent entitled ‘Adenosine A3 receptor agonists for the treatment of dry eye disorders including Sjogren’s syndrome’ from the European Patent Office.
The patent is related to OphthaliX's drug candidate CF101, an orally bioavailable drug being developed for the treatment of ophthalmic indications.
OphthaliX has exclusive rights for the use of CF101 for the treatment of Sjogren's syndrome in Europe until 2025, following the licensing agreement between Can-Fite and its wholly owned subsidiary, EyeFite Ltd.
OphthaliX is currently developing CF101, an A3 adenosine receptor agonist, for ophthalmic indications that includes dry eye syndrome (Phase III), glaucoma (Phase II) and uveitis (initiating Phase II).
Can-Fite BioPharma is also developing CF101 for the treatment of autoimmune inflammatory diseases, rheumatoid arthritis (Phase IIb) and psoriasis (Phase II/III).
Sjogren's syndrome is a systemic autoimmune disease in which immune cells attack and destroy the exocrine glands that produce tears and saliva.